Stock 1952 EVEREST MEDICINES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:34 2024-06-21 EDT 		5-day change 1st Jan Change
19.8 HKD -1.00% Intraday chart for Everest Medicines Limited -2.22% -5.26%
06-10 Transcript : Everest Medicines Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
05-14 Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Everest Medicines Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise
MT
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China
CI
Everest Medicines Commercially Launches Kidney Disease Drug in China
MT
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
AQ
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau
CI
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients
CI
Everest Medicines' Loss Widens in 2023
MT
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
AQ
Transcript : Everest Medicines Limited, 2023 Earnings Call, Mar 27, 2024
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
AQ
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
CI
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
AQ
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
PR
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
PR
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine
AQ
Calliditas Year-end report, January - December 2023
AQ
Everest Medicines Announces Termination of Collaboration Agreements with Providence
AQ
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1952 Stock
  4. News Everest Medicines Limited